Bonita David P 4
4 · ImageneBio, Inc. · Filed Apr 16, 2026
Research Summary
AI-generated summary of this filing
ImageneBio (IMA) Director Bonita David Buys 721,292 Pre-Funded Warrants
What Happened
- Bonita David (Director) is listed on a Form 4 reporting acquisitions on April 14, 2026 of a total of 721,292 derivative securities (reported as purchases). These are pre-funded warrants issued in a private placement: 336,603 and 384,689 pre-funded warrants in two line items. The purchase price per pre-funded warrant was $5.199, implying total consideration of roughly $3.75 million. Pre-funded warrants are derivatives that can be exercised into common shares.
Key Details
- Transaction date: April 14, 2026 (reporting period 2026-04-14).
- Instruments: Pre-funded warrants (derivative acquisitions), two entries of 336,603 and 384,689 for a total of 721,292.
- Price: $5.199 per pre-funded warrant (per footnote); total ≈ $3.75M.
- Exercise terms: Warrants exercisable any time after issuance, subject to a 19.99% beneficial ownership blocker; they expire once exercised in full.
- Record holders: The warrants are held of record by OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P.; related OrbiMed entities may have voting/investment power per footnotes.
- Beneficial-ownership note: Footnotes state the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
- Shares owned after transaction / filing timeliness: Not specified in the provided data.
Context
- Pre-funded warrants are a way for investors to buy near-term rights to common shares (they become common stock upon exercise). The 19.99% blocker prevents immediate exercise that would push ownership above that threshold without further approvals.
- This report documents a private placement to institutional investors (OrbiMed funds); footnotes indicate these are record-held by funds and include standard disclaimers about beneficial ownership — meaning the filing reflects the private-placement structure and related reporting, not necessarily a personal cash purchase by the director in the usual open-market sense.
Insider Transaction Report
Form 4
Bonita David P
Director
Transactions
- Purchase
Pre-Funded Warrants (right to buy)
[F1][F2][F3][F5]2026-04-14+336,603→ 336,603 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (336,603 underlying) - Purchase
Pre-Funded Warrants (right to buy)
[F1][F2][F4][F5]2026-04-14+384,689→ 384,689 total(indirect: See Footnote)Exercise: $0.00→ Common Stock (384,689 underlying)
Holdings
- 753,062(indirect: See Footnote)
Common Stock
[F3][F5] - 20,691(indirect: See Footnote)
Common Stock
[F4][F5]
Footnotes (5)
- [F1]On April 12, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional and accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to OrbiMed Private Investments VI, LP ("OPI VI") and OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund") in a private placement which closed on April 14, 2026 (the "Closing Date") pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 721,292 Shares. The price per Pre-Funded Warrant is $5.199.
- [F2]The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 19.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
- [F3]These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
- [F4]These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
- [F5]Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/ David P. Bonita|2026-04-16